Firefly Neuroscience, Inc.
AIFFTechnologyNASDAQSoftware - Application · Last scanned Oct 26, 2026
Scan Results
Daily timeframeFirefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the. The $14.4M market capitalization puts AIFF squarely in micro-cap range for its industry. The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury.
Market Cap
$14.4M
Beta
-4.04
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.59
EPS (Fwd)
—
ROE
-68.1%
ROA
-34.8%
Cash
$9.2M
Total Debt
$0
Free CF
-$4.4M
52W Change
-54.7%
Annual Financials
Cash vs Debt
Where AIFF stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AIFF finished 31.97% below its 150-day moving average ($1.47) and 27.01% below its 200-day moving average ($1.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AIFF overbought or oversold?
At the October 20, 2026 close, AIFF's RSI(14) was 4.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Firefly Neuroscience, Inc. reports $9.2M in cash and $0 in total debt. Free cash flow is running at -$4.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -68.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -4.04 suggests AIFF is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Firefly Neuroscience, Inc. and its sector.